Antipsychotics are associated with adverse effects. Clinicians should adhere to conscious monitoring of the adverse effects related to use with antipsychotics. Experts have formulated recommendations regarding monitoring parameters to assist with prevention, early detection, and management of potential adverse effects.
Changes in cytochrome P450 (CYP) enzyme metabolism are a common cause of drug-drug interactions. Several psychotropic agents are significantly impacted by CYP interactions or cause interactions by inhibiting or inducing CYP metabolism.
No summary available
No summary available
American Psychiatric Association (APA) Practice guideline for the treatment of patients with schizophrenia (2020) British Association for Psychopharmacology (BAP)
European guidelines Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present, and future. Borderline Personal Disord Emot Dysregul. 2019;6:9. doi: 10.1186/s40479-019-0106-3. [Weblink] World Federation of Societies of Biological Psychiatry (WFSBP)
American Academy of Neurology (AAN) Oral and topical treatment of painful diabetic polyneuropathy practice guidelines (2021) American Diabetes Association
Amyotrophic Lateral Sclerosis (ALS) ALS Canada Canadian best practice recommendations for the management of amyotrophic lateral sclerosis (2020) American Academy of Neurology (AAN)
Agency for Healthcare Research and Quality (AHRQ)/ Patient-Centered Outcomes Research Institute (PCORI)
Academy for Eating Disorders (AED) The AED Guide to Selecting Pharmacologic Treatments for Patients with Eating Disorders (2021) American Academy of Family Physicians (AAFP)
American Academy of Child & Adolescent Psychiatry Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders (2022) American Academy of Pediatrics
American Headache Society (AHS)
American Academy of Pediatrics issues guidance on leucovorin (folinic acid): The AAP does not recommend routine use of leucovorin (folinic acid) for autistic children due to limited evidence on its safety and effectiveness, according to new interim guidance.
Read the latest news from the AAPP Foundation.
Kaleidoscope Newsletter April 2025 Kaleidoscope Newsletter AAPP Foundation President's Message: Spring 2024 AAPP 2025 Activities Sponsored by the AAPP Foundation Trauma Informed Care Session Session at AAPP 2025
American Academy of Neurology Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury | Neurology American College of Emergency Physicians (ACEP)
Insomnia American Academy of Neurology (AAN) Treatment for insomnia and disrupted sleep behavior in children and adolescents with autism spectrum disorder (2020) American Academy of Sleep Medicine (AASM)
American Academy of Child & Adolescent Psychiatry Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder (2007) American Psychiatric Association
Alcohol Use Disorder American Association of Psychiatric Pharmacists (AAPP) Pharmacist toolkit: Alcohol use disorder (2023) American Psychiatric Association (APA)
Medication-induced movement disorders are a variety of iatrogenic and clinically distinct movement disorders caused by various psychiatric medications. The disordered movements can range from tremors to life-threatening syndromes. Movement disorders are classified based on the time of onset after drug ingestion (acute, subacute, or tardive), offending medication, and specific type(s) of abnormal movement. Extrapyramidal Symptoms